Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sho Tachino

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Cancer Immunology, Immunotherapy : CII|January 1, 2013
Functional human Th17 clones with WT1-specific helper activitySho Tachino, Fumihiro Fujiki, Yoshihiro Oka, et al.
Anticancer Research|December 11, 2012
Recognition of a natural WT1 epitope by a modified WT1 peptide-specific T-cell receptorTaichi Tamanaka, Yoshihiro Oka, Fumihiro Fujiki, et al.
Plos One|February 28, 2019
Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathwayYu Kato, Kimiyo Tabata, Takayuki Kimura, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|March 19, 2013
HLA-DPB1*05: 01-restricted WT1332-specific TCR-transduced CD4+ T lymphocytes display a helper activity for WT1-specific CTL induction and a cytotoxicity against leukemia cellsYuhung Lin, Fumihiro Fujiki, Akiko Katsuhara, et al.
Cancer Research Communications|November 11, 2025
Correction: Inhibition of Notch4 Using Novel Neutralizing Antibodies Reduces Tumor Growth in Murine Cancer Models by Targeting the Tumor EndotheliumJason W-L Eng, Yu Kato, Yusuke Adachi, et al.
Cancer Research Communications|July 10, 2024
Inhibition of Notch4 Using Novel Neutralizing Antibodies Reduces Tumor Growth in Murine Cancer Models by Targeting the Tumor EndotheliumJason W-L Eng, Yu Kato, Yusuke Adachi, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Cancer Immunology, Immunotherapy : CII|January 1, 2013
Functional human Th17 clones with WT1-specific helper activitySho Tachino, Fumihiro Fujiki, Yoshihiro Oka, et al.
Anticancer Research|December 11, 2012
Recognition of a natural WT1 epitope by a modified WT1 peptide-specific T-cell receptorTaichi Tamanaka, Yoshihiro Oka, Fumihiro Fujiki, et al.
Plos One|February 28, 2019
Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathwayYu Kato, Kimiyo Tabata, Takayuki Kimura, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|March 19, 2013
HLA-DPB1*05: 01-restricted WT1332-specific TCR-transduced CD4+ T lymphocytes display a helper activity for WT1-specific CTL induction and a cytotoxicity against leukemia cellsYuhung Lin, Fumihiro Fujiki, Akiko Katsuhara, et al.
Cancer Research Communications|November 11, 2025
Correction: Inhibition of Notch4 Using Novel Neutralizing Antibodies Reduces Tumor Growth in Murine Cancer Models by Targeting the Tumor EndotheliumJason W-L Eng, Yu Kato, Yusuke Adachi, et al.
Cancer Research Communications|July 10, 2024
Inhibition of Notch4 Using Novel Neutralizing Antibodies Reduces Tumor Growth in Murine Cancer Models by Targeting the Tumor EndotheliumJason W-L Eng, Yu Kato, Yusuke Adachi, et al.
Pageof 1